 |
 |
||||||||
|
|||||||||
|
|||||||||
 |
 |
||||||||
|
 |
Multiple Antibiotic Resistance (“MAR”) Program Paratek is exploiting the discovery of the Multiple Antibiotic Resistance (“mar”) operon, a novel “master switch” that controls a large set of genes in a number of disease-causing gram-negative bacteria (such as Salmonella, Shigella, and E. coli). Paratek is working to develop drugs that can interfere with this master switch, thereby disabling bacterial resistance mechanisms and rendering bacterial cells ultrasensitive to antimicrobial agents. Paratek’s MAR products could be used in combination with currently marketed antibiotics, such as fluoroquinolones, penicillins, and cephalosporins, to enhance their potency. Paratek is also exploring the role of the mar locus as a target for new prophylactic anti-infective agents for the protection of individuals at risk of infection. The MAR product may also be used to develop disinfectants that may be used in hospitals or at home.
|
